This COVID-19 roundup includes coverage on the latest estimated number of adults with long COVID, WHO’s updated terminology for pathogens that transmit through the air, how COVID-19 vaccination reduces the...
Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...
Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...
Researchers set out to determine whether microglial activation, which can trigger neuroinflammation, is associated with neuropsychiatric symptoms that often accompany Alzheimer-associated dementias,...
The FDA has approved sotatercept-csrk, the first activin signaling inhibitor therapy, for the management of patients with pulmonary arterial hypertension (PAH). Based on the Phase 3 STELLAR trial,...
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
Researchers conducted a systematic review to assess the effect of CPAP treatment for obstructive sleep apnea on secondary cardiovascular disease events.
Researchers evaluated whether patients with atherosclerotic cardiovascular disease (ASCVD) are utilizing high-intensity statins in their routine care of the disease.
This COVID-19 roundup includes coverage of the FDA’s guidance for the correct Moderna vaccine dosage for pediatric patients, COVID-19 outcomes for patients with hypertension and diabetes, and the risk of...
The US Preventive Task Force (USPSTF) expanded upon their previous recommendations on screening for hypertensive disorders, including gestational hypertension, in patients who are pregnant.
